Imaging in cervical cancer

ESGO eAcademy, Faculty / Presenters, 374703

The importance of pathological ultrastaging for sentinel lymph node biopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

ESGO eAcademy, Roman Kocian, 373749

Paradigm shift in recurrent/ metastatic cervical cancer? What to expect and what to look for? Live Q&A

ESGO eAcademy, Faculty / Presenters, 374815

Conversations and Controversies in First-line Maintenance Therapy for Advanced Ovarian Cancer: Summary of the session

ESGO eAcademy, Philipp Harter, 374431

Transforming the future of advanced ovarian cancer care: What can we look forward to in 2023 and beyond?

ESGO eAcademy, Antonio Gonzalez Martin, 374430

Addressing unmet needs: How can we overcome current treatment challenges and improve outcomes in advanced ovarian cancer?

ESGO eAcademy, Toon Van Gorp, 374429

PARP inhibitors in the first-line maintenance setting: How can we use the latest data to guide clinical decision-making?

ESGO eAcademy, Philipp Harter, 374428

New approaches at the horizon for 2L+ treatment of r/m CC

ESGO eAcademy, Faculty / Presenters, 373738

Current developments in 2L treatment of r/m CC

ESGO eAcademy, Faculty / Presenters, 373739

Recent and possible future changes in 1L treatment of r/r CC

ESGO eAcademy, Faculty / Presenters, 373736

Vulvar and clitoral reconstruction using bilateral Singapore island perforator flap after anterior vulvectomy

ESGO eAcademy, Martina Angeles Fite, 373728

MIS in Early Cervical Cancer: No longer a standard

ESGO eAcademy, Pedro Ramirez, 373735

MIS in Early Cervical Cancer: Still Oncologically Safe

ESGO eAcademy, Henrik Falconer, 373734

Synthesizing the Data: Moving forward!

ESGO eAcademy, David Cibula, 373733

Recurrent Cervical Cancer Case With Sacral Metastasis

ESGO eAcademy, Emin Erhan Donmez, 373732

Minimally invasive inguinal lymph node dissection technique

ESGO eAcademy, Hisham Abdel Mageed, 373731

Coloanal anastomosis after exenteration for recurrent cervical cancer

ESGO eAcademy, Luis Chiva, 373730

Total Excision of Infrarenal Vena Cava in a Patient with Recurrent Endometrial Cancer

ESGO eAcademy, Emin Erhan Donmez, 373729

Rechallenge of bevacizumab: current evidence and potential clinical opportunities

ESGO eAcademy, Jean-Emmanuel Kurtz, 373726

Surgery in relapsed ovarian cancer: whom, who, when, and how

ESGO eAcademy, Florian Heitz, 373727

PARP after PARP: what have we learned from the OREO/ENGOT-OV38 study

ESGO eAcademy, Antonio Gonzalez Martin, 373725

Overview of the new quality indicators for cervical cancer management

ESGO eAcademy, Christina Fotopoulou, 373724

What is a high quality external beam radiotherapy for cervical cancer?

ESGO eAcademy, Cyrus Chargari, 373723

Quality indicators for uterovaginal brachytherapy

ESGO eAcademy, Remi Nout, 373722

Rectovaginal fistula repair by Martius flap after exclusive chemo-radiation in advanced cervical cancer patient. A case report

ESGO eAcademy, Vito andrea Capozzi, 373721

The case of laparoscopic anterior rectal resection and retransplantaion of theureter with the use of ICG.

ESGO eAcademy, Ewa Milnerowicz-Nabzdyk, 373720

Total resection of aggressive pelvic angiomyxoma by combination of robotic & vaginal approach.

ESGO eAcademy, Sergi Fernandez, 373719

Laparoscopic cytoreducion for relapsed gynaecological cancer

ESGO eAcademy, Ignacio Zapardiel, 373718

Agressive angiomyxoma of the pelvis and vagina: a robotic and vaginal combined approach

ESGO eAcademy, Luzarraga Anna, 373717

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ)

ESGO eAcademy, Radoslav Chekerov, 373716

A predictive model for detection of epithelial ovarian cancer based on methylation landscape

ESGO eAcademy, Douglas VNP Oliveira, 373715

Intermediate-risk endometrial cancer: isolated tumor cells (ITC) versus node-negative in sentinel lymph node mapping. An international multi-institutional comparative study

ESGO eAcademy, Giuseppe Cucinella, 373714

Identifying women with early-stage cervical cancer at low risk of lymph node metastases, in a large international cohort - A logistic regression analysis, without sharing privacy-sensitive patient data

ESGO eAcademy, Hans Wenzel, 373713

The role of molecular classification in endometrial cancers with lymph nodes metastasis.

ESGO eAcademy, Gabriella Schivardi, 373712

BACK TO THE FUTURE: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification

ESGO eAcademy, Emanuele Perrone, 373711

Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment

ESGO eAcademy, Giulio Bonaldo, 373709

Symptomatic or asymptomatic recurrence of ovarian cancer: Does it influence survival?

ESGO eAcademy, Karen Madland, 373708

The significance of lower uterine segment involvement in endometrial cancer

ESGO eAcademy, Sharon Davidesko, 373707

The MULTISENT study: Analysis of survival according to the volume of sentinel lymph node disease

ESGO eAcademy, Silvia Cabrera Diaz, 373704

Pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with Niraparib

ESGO eAcademy, Serena Maria Boccia, 373703

Comparison of PD-L1 status between primary and paired recurrent/metastatic cervical cancer

ESGO eAcademy, Beyhan Ataseven, 374704

HRD-positive ovarian cancer: PARP inhibitors, bevacizumab - how to choose maintenance therapy in practice

ESGO eAcademy, Isabelle Ray-Coquard, 373699

Surgical aspects for early, advanced stage and recurrent disease

ESGO eAcademy, Anna Fagotti, 373702

BRCA mutated ovarian cancer: PARP inhibitors, bevacizumab- how to choose maintenance therapy in practice

ESGO eAcademy, Susana Banerjee, 373697

HRD-negative ovarian cancer: how to choose maintenance therapy in practice and future options

ESGO eAcademy, Antonio Gonzalez Martin, 373698

Medical options in different ovarian cancer populations

ESGO eAcademy, Jonathan Ledermann, 373701

Pathology and molecular biology

ESGO eAcademy, Xavier Matias-Guiu, 373700

New Era of Immune Checkpoint Inhibitors in Endometrial Cancer: Q&A

ESGO eAcademy, Faculty / Presenters, 374425

The Future of ICI – PD-1/L1 Inhibitors in First-line Treatment of Endometrial Cancer

ESGO eAcademy, Mansoor Raza Mirza, 374424

Diagnosis and Treatment of Advanced EC: Patient Case Study

ESGO eAcademy, Christian Marth, 374423

Treatment of Recurrent EC with ICI: Patient Case Study

ESGO eAcademy, Lucy Gilbert, 374422

Where do Immune Checkpoint Inhibitors Fit in the Patient Journey?

ESGO eAcademy, Jalid Sehouli, 374421

Discussant

ESGO eAcademy, Toon Van Gorp, 373688

The development of immunotherapy in gestational trophoblastic tumours

ESGO eAcademy, Benoit You, 373696

Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: a prospective, open-label, randomized controlled phase

ESGO eAcademy, Zhiying Xu, 373687

The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

ESGO eAcademy, Domenica Lorusso, 373689

Management of Gestational Trophoblastic Tumours: Discussion about an illustrative patient case

ESGO eAcademy, Christian Marth, 373695

Role of chemotherapy and identification of new biological targets for drug development in gestational trophoblastic disease

ESGO eAcademy, Gloria Marquina, 373694

Pembrolizumab Monotherapy for Advanced Clear Cell Gynaecological Cancer: Phase II PEACOCC Trial

ESGO eAcademy, Rowan Miller, 373691

Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer

ESGO eAcademy, Nanda Horeweg, 373690

Helga Salvesen Award for Best Translational Research: Introduction and announcement of the award

ESGO eAcademy, Mansoor Raza Mirza, 373686

ENGOT, ENYGO & ENGAGe Anniversary talk

ESGO eAcademy, Mansoor Raza Mirza, 373685

ESGO Presidential talk on ESGO 2022

ESGO eAcademy, Nicole Concin, 373684

Decoding Chaos - analysing the genome of ovarian high grade serous carcinoma

ESGO eAcademy, Iain McNeish, 373683

Pro robotics surgery, new options and indications

ESGO eAcademy, Henrik Falconer, 373681

Pro laparoscopic surgery, a conventional method with innovative possibilities

ESGO eAcademy, Mustafa Zelal Muallem, 373680

Major achievements in the management of ovarian cancer (SOLO1, PAOLA1, PRIMA, ATHENAmono, Atalante)

ESGO eAcademy, Mansoor Raza Mirza, 373679

Advances in endometrial & cervical cancers (ENGOT-EN6, KN775, KN826, EMPOWER, ENGOT-CX6)

ESGO eAcademy, Nicoletta Colombo, 373678

Introduction and announcement of competition

ESGO eAcademy, Anna Fagotti, 373682

Histopathology and staging of the disease

ESGO eAcademy, Alexandros Rodolakis, 373677

Fertility related issues, pregnancy, and ART

ESGO eAcademy, Kirsten Tryde Macklon, 373676

New ESGO-ESHRE-ESGE Guidelines on Fertility Sparing in Endometrial Cancer: Medical treatment

ESGO eAcademy, Giovanni Scambia, 373675

Oral posters session 2 : ID 648 - 999 - 922

ESGO eAcademy, Faculty / Presenters, 373668

Oral posters session 2 : ID 604 - 745 - 641

ESGO eAcademy, Faculty / Presenters, 373665

Clinical relevance of clinicopathological and molecular factors in women with surgically treated stage IV endometrial cancer

ESGO eAcademy, Linda Nooij, 373663

Oral posters session 2 : ID 781 - 1569 - 568

ESGO eAcademy, Faculty / Presenters, 373662

Session 3 | Communicative skills training

ESGO eAcademy, Faculty / Presenters, 374598

Session 4 | Burnout

ESGO eAcademy, Faculty / Presenters, 374599

Welcome speech on ESGO 2022

ESGO eAcademy, Faculty / Presenters, 373661

All patients should have molecular testing - Con

ESGO eAcademy, Glenn McCluggage, 373654

Molecular classification for management of endometrial cancer: Discussion

ESGO eAcademy, Christian Marth, 373656

Managing the challenge of combination therapies with immune checkpoint inhibitors: 2. Anti-angiogenic therapy

ESGO eAcademy, Jonathan Ledermann, 373657

How to manage the side effects of single-agent immune checkpoint inhibitors

ESGO eAcademy, Ana Oaknin, 373658

Managing the challenge of combination therapies with immune checkpoint inhibitors: 1. Chemotherapy

ESGO eAcademy, Nicoletta Colombo, 373659

All patients should have molecular testing - Pro

ESGO eAcademy, Domenica Lorusso, 373655

Surgery of the vulva and plastic reconstruction

ESGO eAcademy, Sven Mahner, 373653

Surgery of the lymph nodes - groin and pelvis

ESGO eAcademy, Linn Woelber, 373652

Surgery for recurrence with pelvic exenteration

ESGO eAcademy, Nadeem R. Abu-Rustum, 373651

New Keystone flap application in vulvo-perineal reconstructive surgery for vulvar cancer.

ESGO eAcademy, Alfonso Altieri, 373650

Low anterior resection for advanced ovarian carcinoma, technical considerations to minimize postoperative complications

ESGO eAcademy, Ane Gerda Eriksson, 373648

Protected Laparoscopic Large Ovarian Cyst Aspiration - A five steps alternative to laparotomy

ESGO eAcademy, Houssein El Hajj, 373647

Transvaginal single port laparoscopic for left ovarian cyst removal and bilateral tubal anastomosis

ESGO eAcademy, Ling Min, 373646

Impact of vaginal morbidity on sexual health in cervical cancer—insights from the EMBRACE study

ESGO eAcademy, Kathrin Kirchheiner, 373645

Impact of dilation and sexual activity on vaginal morbidity—preliminary results

ESGO eAcademy, Remi Nout, 373644

ENYGO-ENGAGe survey on sexual health after gynaecological cancer—preliminary results

ESGO eAcademy, Zoia Razumova, 373643

Pathology update

ESGO eAcademy, Maria Rosaria Raspollini, 373642

Definitive chemoradiation and brachytherapy

ESGO eAcademy, Jacob Lindegaard, 373641

Systemic treatment in advanced and metastatic disease

ESGO eAcademy, Remi Nout, 373640

Surgical treatment (T1a, T1b1-T1b3, FST, Cancer in pregnancy, Cancer from specimen after hysterectomy)

ESGO eAcademy, David Cibula, 373639

Validation Study of the “NOGGO-GIS ASSAY” based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

ESGO eAcademy, Lukas C. Heukamp, 373636